Dashboard
1
With a Operating Losses, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of 2.85% and Operating profit at -383.94% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
2
Negative results in Mar 25
3
Risky -
Stock DNA
Pharmaceuticals & Biotechnology
CNY 14,477 Million (Large Cap)
NA (Loss Making)
NA
0.00%
1.16
-70.63%
49.45
Revenue and Profits:
Net Sales:
109 Million
(Quarterly Results - Jun 2025)
Net Profit:
-41 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-19.13%
0%
-19.13%
6 Months
156.55%
0%
156.55%
1 Year
240.6%
0%
240.6%
2 Years
233.38%
0%
233.38%
3 Years
126.67%
0%
126.67%
4 Years
193.22%
0%
193.22%
5 Years
145.38%
0%
145.38%
Fujian Cosunter Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
2.85%
EBIT Growth (5y)
-383.94%
EBIT to Interest (avg)
-7.71
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.98
Sales to Capital Employed (avg)
0.42
Tax Ratio
6.48%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0.56%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
49.45
EV to EBIT
-79.69
EV to EBITDA
-173.12
EV to Capital Employed
23.47
EV to Sales
35.06
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-29.45%
ROE (Latest)
-70.63%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
108.70
95.50
13.82%
Operating Profit (PBDIT) excl Other Income
-5.60
4.70
-219.15%
Interest
8.30
8.40
-1.19%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-40.90
-29.50
-38.64%
Operating Profit Margin (Excl OI)
-280.90%
-211.20%
-6.97%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 13.82% vs -15.19% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -38.64% vs 70.11% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
432.00
413.90
4.37%
Operating Profit (PBDIT) excl Other Income
-46.20
-134.60
65.68%
Interest
35.60
35.30
0.85%
Exceptional Items
-14.20
0.70
-2,128.57%
Consolidate Net Profit
-172.50
-374.90
53.99%
Operating Profit Margin (Excl OI)
-341.20%
-512.30%
17.11%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 4.37% vs 9.79% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 53.99% vs -166.64% in Dec 2023
About Fujian Cosunter Pharmaceutical Co., Ltd. 
Fujian Cosunter Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






